Delving into the Latest Updates on Yiming Biomedical Technology (Hangzhou) Co., Ltd. with Synapse

Overview

评价IO-108在晚期或转移性实体瘤受试者中的安全性和耐受性，确认中国患者的II期推荐剂量（RP2D）；评价IO-108联合帕博利珠单抗或替雷利珠单抗在晚期或转移性实体瘤患者中的安全性和耐受性，并确认在中国患者中的RP2D；评价IO-108联合帕博利珠单抗或替雷利珠单抗治疗特定晚期或转移性实体瘤患者的初步抗肿瘤活性。

[Translation]

Evaluate the safety and tolerability of IO-108 in subjects with advanced or metastatic solid tumors and confirm the Phase II recommended dose (RP2D) for Chinese patients; Evaluate the safety and tolerability of IO-108 combined with pembrolizumab or tislelizumab in patients with advanced or metastatic solid tumors and confirm the RP2D in Chinese patients; Evaluate the preliminary anti-tumor activity of IO-108 combined with pembrolizumab or tislelizumab in the treatment of specific patients with advanced or metastatic solid tumors.

Start Date26 Aug 2022

Sponsor / Collaborator

Yiming Biomedical Technology (Hangzhou) Co., Ltd.

100 Clinical Results associated with Yiming Biomedical Technology (Hangzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Yiming Biomedical Technology (Hangzhou) Co., Ltd.

Login to view more data

100 Deals associated with Yiming Biomedical Technology (Hangzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Yiming Biomedical Technology (Hangzhou) Co., Ltd.

Login to view more data